Vaccines and kids 2

COVID-19 Vaccine Requirements: Considerations for U.S. Clinical Trial Participants

Nov 03, 2021 | Katherine Waters, Victoria Thompson

As the COVID-19 response evolves, vaccine requirements, sometimes referred to as mandates, are increasingly being used as a tool to improve vaccine uptake. Vaccine requirements, especially when used in specific settings such as the workplace or healthcare facilities, are a long-standing and proven public health strategy for increasing vaccination coverage and decreasing the incidence of morbidity and mortality associated with vaccine-preventable diseases, such as COVID-19. One main way in which vaccine requirements are being utilized is through the Biden Administration’s COVID-19 action plan which outlines vaccination requirements for the following groups:

  • Employers with 100 or more employees are to require vaccination or ensure weekly negative tests for unvaccinated employees;
  • Healthcare workers at Medicare and Medicaid participating hospitals and health care facilities; and
  • Federal workers and contractors that do business with the federal government.

In addition to the COVID-19 vaccines that are authorized and recommended for use in the United States (Moderna, Pfizer, and Janssen), some individuals may have been vaccinated for COVID-19 through a clinical trial in which the vaccine has not yet been approved in the U.S. For the purposes of vaccine requirements, it’s important to understand how to determine if a person who has been vaccinated through one of these trials is considered fully vaccinated. To do so, the Centers for Disease and Control and Prevention (CDC) has issued interim guidance for those who have been vaccinated as part of a clinical trial for a COVID-19 vaccine that is not currently approved or authorized by the Food and Drug Administration (FDA). Current CDC guidance is below.

A person vaccinated against COVID-19 as part of a clinical trial in the U.S. is considered fully vaccinated:

  • Two weeks after receiving the full vaccination series AND
  • The vaccine given is confirmed to have been an active vaccine, not a placebo dose AND
    • The vaccine is listed for emergency use by the World Health Organization (currently the AstraZeneca COVID-19 vaccine meets these criteria) OR
    • The vaccine efficacy has been independently confirmed (currently the Novavax COVID-19 vaccine meets these criteria)

As always, please reference CDC and FDA for the most current information regarding which COVID-19 vaccines have been approved in the United States. For additional information and resources, please see the relevant links below.

Biden Administration’s COVID-19 action plan

Different COVID-19 Vaccines | CDC

COVID-19 Vaccines | FDA

Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC

COVID-19 Workplace Safety: Guidance for Federal Contractors and Subcontractors


About Katherine Waters

More posts by Katherine Waters

About Victoria Thompson

Victoria Thompson is a Senior Program Analyst on the Immunization Team at NACCHO.

More posts by Victoria Thompson

Related Posts

A person reads overdose prevention information
  • Opioid Overdose Epidemic

Funding Announcement: 2023-2024 Harm Reduction and...

We are excited to release the Request for Proposals (RFP) for the 2023-2024...

Oct 02, 2023 | Bailey McInnes

Funding Announcement: 2023-2024 Harm Reduction and...

County health department
  • Tools & Resources
  • Webinar
  • Maternal, Child, & Adolescent Health

How Can Local Health Departments Help Promote...

As we wrap up September, we are highlighting Fetal Alcohol Spectrum Disorders...

Sep 29, 2023 | Ryanna Quazi

How Can Local Health Departments Help Promote...

I Stock 1376581316
  • Funding Opportunity
  • Health & Disability

Request for Proposals: Inclusive Public Health Planning...

NACCHO would like to expand learning opportunities for local health departments...

Sep 29, 2023 | Sara Lyons

Request for Proposals: Inclusive Public Health Planning...

  • HIV, STI, & Viral Hepatitis
  • HIV, STI, Viral Hepatitis, and Harm Reduction Digest

Digest (September 27, 2023)

HIV, STI, Viral Hepatitis, and Harm Reduction Digest: September 27, 2023

Sep 27, 2023

Digest (September 27, 2023)

Microsoft Teams image 15
  • HIV, STI, & Viral Hepatitis

EHE Superstars: Using Art to Improve Youth HIV Awareness...

This is the first blog in a new series highlighting collaborative work between...

Sep 25, 2023 | Julia Zigman, Anthony Green

EHE Superstars: Using Art to Improve Youth HIV Awareness...

Opportunity
  • Funding Opportunity
  • Adverse Childhood Experiences (ACEs)

Request for Proposals: Suicide, Overdose, and Adverse...

Applicaitons due Friday, October 27.

Sep 25, 2023 | Camille Adams

Request for Proposals: Suicide, Overdose, and Adverse...

Request for Proposals: Development of a Congenital...

NACCHO is seeking a consultant to begin the creation of a draft quality measure...

Sep 22, 2023

Request for Proposals: Development of a Congenital...

At home testing
  • COVID-19
  • Immunization
  • Infectious Disease

Free COVID Tests Available Again to Households

Beginning September 25, households will again be able to order four free tests...

Sep 21, 2023 | Beth Hess

Free COVID Tests Available Again to Households

  • HIV, STI, & Viral Hepatitis

Key Learnings and Recommendations from the American...

NACCHO has created a final report sharing key takeaways from this convening.

Sep 19, 2023

Key Learnings and Recommendations from the American...

Back to Top